Sami Labs Limited

Sabinsa Corporation

Other

Sami-sabinsa Group Limited

Signpath Pharma, Inc.

Semi Labs Limited

Sami Chemicals & Extracts, Ltd.

Muhammed Majeed

Kalyanam Nagabhushanam

Sivakumar Arumugam

Furqan Ali

Subbalakshmi Prakash

Lakshmi Mundkur

Shaheen Majeed

Anjali Pandey

Rajendran Ramanujam

Vladimir Badmaev

Sarang Bani

Beena Bhat

Samuel Manoharan Thomas

Anju Majeed

R Rajendran

Kirankumar Beede

Priti Vaidyanathan

Rajinder Kumar Bammi

Renukeshwar H Chandramouli

Lawrence Helson

Annie Bouchard

Keshava Rapole

George M Shopp

Natarajan Sankaran

Savita Ganjihal

Ravikrishna Chebolu

Rattan Sood

Krishnamani Jayaraman

Suresh Karri

Douglas Kalman

Ramaswamy Rajendran

Susmitha Anand

Mitchell Chavez

Geetha Kanhangad-Gangadharan

Anurag Pande

Nagabhushanam Kalyanam

Nagarajan Ananthanarayanan

Sankaran Natarajan

Jeffrey Reinhardt

Walter Allen Shaw

Stephen W Burgess

Muthuraman Gnanamani

Shipra Roy

Kalyanam Nagebhuananam

Kiran Trineshwaraiah-Sirsalmath

Nooruddin Thajuddin

Sivaprakash Kurumanghat Balakrishnan

KalkunteSeshadri Satyan

KanhangadGangadharan Geetha

Tirumale Sharmila

Venu Agarwal

Arvind Kumar

Vladimir Hadmaev

Viadimir Badmaey

Ramanujam Rajendran

Seena George

Sivaprskash Kurumanghat Balakrishnan

Hosahalli Prabhakara Hemantha

Mahadeva Nayak

Prasad M Peethambaran

Jamsheeda Moothedath

Bani Sarang

Jefferey Reinhardt

John Adams Sebastian

Susmitha Anand Tathapudi

Samuel Thomas Manoharan

Garima Agarwal

Susmitha Anand-Tathapudi

Pritee Paliwal

Sakthivel Palaniappan

Ambady Rajagopalan

Rajasekharan Parthasarathy

Krishnamurthy Kulithalai Viswanathan

Kalyanam Nagabushnam

Stephen Burgess

Disclosed are the skin care applications of a composition containing the partially purified extracellular metabolite isolated fromMTCC 5856. More specifically, the invention discloses the ability of the partially purified extracellular metabolite isolated fromMTCC 5856 to confer protection to the skin fibroblasts against UV induced cell damage and apoptosis, oxidative stress and inflammation.

Skin care applications of extracellular metabolites from Bacillus coagulans

The present invention discloses a method for therapeutic management of pulmonary fibrosis in mammals using a composition comprising iso-garcinol or octahydrocurcumin or a combination of iso-garcinol and octahydrocurcumin. The composition is very suitable for treating pulmonary fibrosis due to viral infections, specifically COVID 19 and for improving lung function during prognosis.

Therapeutic compositions and methods for pulmonary fibrosis

The present invention discloses a composition comprising 70%-80% w/w tetrahydrocurcuminoids, 10%-20% w/w hexahydrocurcuminoids and 5%-10% w/w octahydrocurcuminoids and its therapeutic application. More specifically, the present invention discloses the use of a composition comprising 70%-80% w/w tetrahydrocurcuminoids, 10%-20% w/w hexahydrocurcuminoids and 5%-10% w/w octahydrocurcuminoids in the therapeutic management of metabolic syndrome in mammals.

Curcuminoid composition for therapeutic management of metabolic syndrome

The present invention discloses a composition comprising 70%-80% w/w tetrahydrocurcuminoids, 10%-20% w/w hexahydrocurcuminoids and 5%-10% w/w octahydrocurcuminoids and its therapeutic application. More specifically, the present invention discloses the use of a composition comprising 70%-80% w/w tetrahydrocurcuminoids, 10%-20% w/w hexahydrocurcuminoids and 5%-10% w/w octahydrocurcuminoids in the therapeutic management of interstitial lung disease or lung fibrosis.

Curcuminoid composition and its therapeutic potential in managing lung fibrosis

Disclosed are the uses of compositions containing not less than 10% w/w of Oroxylin A, not less than 10% w/w of Baicalein and not less than 2% w/w of Chrysin in inhibiting the activity and expression of &#x3b2; secretase. The invention also discloses the reduction of amyloid content in PS-70 cells using the abovementioned composition. Further, the invention mentions the use of the composition for the therapeutic management of &#x3b2; secretase mediated disorders.

Compositions and methods for beta secretase inhibition

The present invention discloses the potential of probiotic bacteriaindividually or in combination with multi-enzyme complex for reducing gluten content in foods rich in gluten and for the increased utilization of gluten. The invention further discloses a method for the management of gluten intolerance using composition comprisingand multi-enzyme complex in mammals.

Method and composition for therapeutic management of gluten intolerance

The present invention discloses a method for therapeutic management of atrophic gastritis and colitis using a composition comprisingMTCC 5856 individually or in combination with anthocyanins. The invention further discloses a method for preventing neoplastic transformation of mucosal cells in gastro-intestinal tract and improving gut barrier function in mammals using a composition comprisingMTCC 5856 individually or in combination with anthocyanins.

Compositions and methods for management of atrophic gastritis and colitis

The present invention discloses a method for protecting mammalian skin against the harmful effects of UV radiation and environmental pollutants, using one or plant actives selected from group comprising a composition comprising not less than 10% w/w oroxylin A, not less than 10% w/w baicalein and not less than 2% w/w chrysin; 95% w/w oxyresveratrol; 95% w/w tetrahydrocurcumin; 90% w/w pterostilbene and a composition comprising at least 10% w/w &#x3b2;-glucogallin and at least 10% w/w total mucic acid gallates. The invention also discloses a method for cleansing and rejuvenating mammalian skin, exposed to environmental pollutants and UV radiation using the aforesaid plant actives.

Plant actives and their anti-pollution effects thereof

A probiotic-alcoholic beverage composition comprisingis disclosed herein wherein the said spore or vegetative cell ofexhibited high recovery, tolerability, compatibility and viability of spores and vegetative cells after brewing. Methods for brewing an alcoholic beverage composition comprisingwherein said spore or bacterium is added during pre-fermentation, during fermentation and post fermentation stages are also disclosed.

Alcoholic beverage composition containing

The present invention relates to a process for the isolation of bioactive components from spent turmeric () and compositions comprising said bioactive components. Further, the present invention also elucidates the potent anti-inflammatory activity of said bioactive compositions and therapeutic applications thereof in rheumatoid arthritis.

Isolates from spent turmeric for the management of rheumatoid arthritis

The present invention discloses a novel endophytic fungi,MTCC 25236 for the bioconversion of curcuminoids to Calebin-A and a method for its isolation from the rhizomes ofsp. The invention also discloses a method for the bioconversion of curcuminoids to Calebin-A using an endophytic fungiMTCC 25236 and bacterial species,and

Microbial bioconversion of curcuminoids to calebin-A

The present invention discloses a composition comprising heat inactivated spores and/or comprising heat inactivated vegetative cells of probiotic bacteria, and a process for preparing the same. The invention also discloses a method of modulating immune function in mammals by activating macrophages, using a composition comprisingin the form of live or heat inactivated spore and/or vegetative cells.

Modulation of immune function by

Disclosed is the hypolipidemic potential of. More specifically the invention discloses the cholesterol lowering potential ofMTCC 5856 and therapeutic/biological indications thereof.

Hypolipidemic effects of

The present invention discloses a stable probiotic composition comprisingindividually and/or in combination with multi-enzyme complex for the utilization of lactose and therapeutic management of lactose intolerance. It also discloses a method for the management of lactose intolerance using composition comprisingindividually and/or in combination with multi-enzyme complex.

Stable probiotic composition for the management of lactose intolerance

The present invention discloses a novel fructophilic lactic acid producing bacteriastrain FF-7 (MTCC 25235) and the process of isolation and characterization of the bacteria. The invention also discloses the biological applications/therapeutic use of fructophilic lactic acid producing bacteria in increased utilization of fructose from food stuff and in the managing disorders related to high fructose intake.

Fructophilic lactic acid producing bacteria

Growing community of inventors

Edison, NJ, United States of America

Muhammed Majeed